SAB Biotherapeutics (SABS) Non Operating Income (2021 - 2026)
SAB Biotherapeutics (SABS) posted Non Operating Income of $1.1 million for Q1 2026, up 203.52% on a QoQ basis from -$1.1 million in Q4 2025, and down 79.75% year-over-year from $5.6 million in Q1 2025.
SAB Biotherapeutics (SABS) Non Operating Income (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Non Operating Income history runs 6 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- Quarterly Non Operating Income fell 79.75% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.8 million (up 620.85% YoY) and the FY2025 annual result came in at $62.2 million, up 606.71% from the prior year.
- Non Operating Income was $1.1 million for Q1 2026 at SAB Biotherapeutics, up from -$1.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $58.1 million in Q3 2025 and bottomed at -$4.0 million in Q4 2023.
- A 5-year average of $4.6 million and a median of $731248.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income tumbled 36168.02% — and 2024, when it surged 13108.14%.
- SAB Biotherapeutics' Non Operating Income stood at $11043.0 in 2022, then tumbled by 36168.02% to -$4.0 million in 2023, then soared by 65.21% to -$1.4 million in 2024, then gained by 21.31% to -$1.1 million in 2025, then jumped by 203.52% to $1.1 million in 2026.
- Business Quant data shows SABS's Non Operating Income at $1.1 million in Q1 2026, -$1.1 million in Q4 2025, and $58.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | 1.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | -1.09 Mn |
| Sep 30, 2025 | 58.12 Mn |
| Jun 30, 2025 | -382,209.00 |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | -1.39 Mn |
| Sep 30, 2024 | 959,956.00 |
| Jun 30, 2024 | 2.87 Mn |
| Mar 31, 2024 | 6.36 Mn |
| Dec 31, 2023 | -3.98 Mn |
| Sep 30, 2023 | 220,605.00 |
| Jun 30, 2023 | -404,268.00 |
| Mar 31, 2023 | 48,189.00 |
| Dec 31, 2022 | 11,043.00 |
| Sep 30, 2022 | 731,248.00 |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 7.79 Mn |
| Dec 31, 2021 | -4.21 Mn |
| Sep 30, 2021 | -70,836.00 |
| Jun 30, 2021 | 94,000.00 |